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The Coronavirus Disease (COVID-19) pandemic caused by the SARS-coronavirus 2 (SARS-CoV-2) urgently calls for the 
design of drugs directed against this new virus. Given its essential role in proteolytic processing, the main protease Mpro has 
been identified as an attractive candidate for drugs against SARS-CoV-2 and similar coronaviruses. Recent high-throughput 
screening studies have identified a set of existing, small-molecule drugs that have already been approved for various diseases 
as potent Mpro inhibitors. Amongst these, Ebselen (2-Phenyl-1,2-benzoselenazol-3-one), a glutathione peroxidase mimetic 
seleno-organic compound, is particularly attractive. Recent experiments suggest that its effectiveness is higher than that of 
other molecules that also act at the enzyme’s catalytic site. By relying on extensive simulations with all-atom models, in this 
study we examine at a molecular level the potential of Ebselen to decrease Mpro’s catalytic activity. Our results indicate that 
Ebselen exhibits a distinct affinity for the catalytic site cavity of Mpro. In addition, our molecular models reveal a second, 
previously unkown binding site for Ebselen in the dimerization region localized between the II and III domains of the protein. 
A detailed analysis of the free energy of binding indicates that the affinity of Ebselen to this second binding site is in fact 
significantly larger than that to the catalytic site. A strain analysis indicates that Ebselen bound between the II-III domains 
exerts a pronounced allosteric effect that regulates catalytic site access through surface loop interactions, and induces a 
displacement and reconfiguration of water hotspots, including the catalytic water, that could interfere with normal enzymatic 
function. Taken together, these findings provide a framework for the future design of more potent and specific Mpro inhibitors, 
based on the Ebselen scaffold, that could lead to new therapeutic strategies for COVID-19. 
  
Introduction: 
A new coronavirus of zoonotic origin, SARS-CoV-2, is the etiological agent responsible for the 2019-2020 viral pneumonia 
COVID-19 outbreak that commenced in Wuhan City, Hubei Province, China (1-4). Currently, targeted therapeutics are not 
available and, at this point in time, effective treatment options remain tentative and very limited. 
Conventional drug design and drug development strategies require years of investigations and substantial investments. The 
repurposing of approved pharmaceutical drugs and drug candidates already in clinical trials therefore provides an essential, 
alternative approach to rapidly identify drugs with clinical potential and to manage new infectious diseases that lack specific 
treatments and vaccines. A recent high-throughput screening study (5) considered more than 10,000 compounds against 
COVID-19. The study included approved drugs, drug candidates and natural products that were screened by an enzymatic 
inhibition assay seeking to find inhibitors of the virus’s main protease, Mpro; Ebselen, a relatively small molecule, emerged 
from that work as a new drug lead to target this crucial enzyme. The structures of Ebselen and Mpro are shown in Figure 1. 
Mpro is a key CoV enzyme, which plays a central role in mediating viral replication and transcription, making it an attractive 
drug target against this virus (6, 7).  
Ebselen, which has also shown strong antiviral activity in cell-based assays (5), is an organoselenium compound with anti-
inflammatory, anti-oxidative, and cytoprotective properties. It has been investigated in the context of multiple diseases, such 
as bipolar disorders (8) and hearing loss (9, 10). In addition, a recent report indicated that Ebselen also showed potent 
bactericidal activity against multidrug-resistant (MDR) clinical isolates of staphylococcus aureus (11). Likewise, the use of 
silver and Ebselen in synergistic formulations have been shown to be effective against five, clinically difficult-to-treat MDR 
Gram negative bacteria (12). Ebselen has extremely low cytotoxicity (LD50 in rats > 4,600 mg/kg, per os) (13), and its safety 
in humans has been evaluated in several clinical trials (9, 10, 14). Taken together, these reports and the underlying data 
underscore the clinical potential of Ebselen for CoV-2 treatment.  
In an effort to understand the molecular mechanisms through which Ebselen interacts with Mpro, in this work we present 
results of atomistic molecular simulations that provide useful, previously unknown insights into the Mpro-Ebselen complex, 
and which might provide new avenues to rationally enhance Ebselen’s activity. First, we present an analysis of the most 
probable interaction sites between Mpro-Ebselen, as well as, absolute binding free energy calculation for a complementary 
quantitative evaluation. Second, we evaluate the role of different binding sites on molecular stiffness and molecular strain. 
Finally, we examine how Ebselen binding modifies the structure and transport of water in Mpro’s catalytic site. We find that 
Ebselen binds to two sites, as opposed to only one at the catalytic site, and we also identify an allosteric mechanism that 
influences the catalytic site when Ebselen is bound at the distant site. Our findings are summarized in a concluding section, 
and several suggestions for future experimental work are presented.  
Results: 
Molecular dynamics simulations of Mpro and Ebselen were carried out using the AMBER18 simulation package (see Methods 
section for details). A total of 3 µs of atomistic molecular dynamics trajectories of Mpro using Ebselen as a molecular probe 
were organized into 15 replicas of 200 ns each. These trajectories were analyzed to construct probability density maps for 
the preferred locations of Ebselen around the protein. The results are shown in Figure 1. Two distinct, highly probable binding 
sites emerged from this analysis. The first is located within the catalytic site, and the second is in a region that is essential for 
Mpro’s dimerization (15), between the II and III domains. Similar observations were reported in a previous study (16), where 
simple organic solvents/compounds such as acetonitrile, benzene, dimethylsulfoxide, methanol, phenol, and urea were used 
as molecular probes. In addition, the authors considered the potential mutability of residues belonging to the Mpro catalytic 
site, and explained that the development of drug resistance associated with the natural evolution of Mpro could wipe out 
efforts that target this protein for COVID-19 treatment. Instead, they emphasized the promise of alternative strategies aimed 
at targeting the region between the II and III domains, which is implicated in dimer formation. The results shown in Figure 1 
are therefore encouraging in that Ebselen appears to target both the catalytic site and the dimerization domain.  
 
Figure 1. Structure of Mpro and density maps of Ebselen binding. (A) lateral view, and (B) top view. In both figures, yellow surfaces show the most 
probable interaction sites between Mpro and Ebselen (highest probability density). Mpro domain I, II and III are shown in red, blue and grey, 
respectively. Cys145 and His41 (the catalytic dyad), are shown in cyan. The loop (residues 185 to 201) connecting domains I and II with domain III is 
shown in pink. The inset shows the chemical structure of the Ebselen molecule.  
 
Figure 2 provides a closer look at Ebselen’s binding motifs in both regions (the catalytic site and the intersection between 
domains II–III). In the catalytic site, Figure 2A, hydrogen bonding interactions are formed between the carbonyl oxygen of 
Ebselen and the Asn142 and Gln189 side chains. One can also appreciate the hydrophobic contacts between Ebselen and 
Met165, Pro168, Met49, His164 and both residues belonging to the catalytic dyad, His41 and Cys145.  
Figure 2B shows a representative configuration of Ebselen at the intersection between domains II and III. There are distinct 
hydrophobic contacts with Phe294, Pro108, Ile200, Val202, His246, Thr292, Ile249, Pro132 and Ile249 (some residues are 
not shown for clarity). Highly dynamic hydrogen bonds were observed between Ebselen and the Gln107, Gln110, and Hie246 
side chains.  
 
Figure 2. Binding modes for Ebselen-Mpro complexes. (A) At the catalytic site, and (B) at the intersection between Domain II-III. In both figures, 
Ebselen, as well as main residues displaying contacts, are showed with sticks.  
The results shown in Figure 1 were generated on the basis of direct molecular dynamics simulations. In order to arrive at a 
quantitative estimate of the binding affinity of each site, we used thermodynamic integration to determine the absolute binding 
free energy for the catalytic site and the Domain II-II site. More specifically, we used Particle Mesh Ewald Molecular Dynamics 
(PMEMD) as implemented in Amber 18 (33) with 11 windows per integration and 10ns per window. In addition, multiple runs 
starting from the most probably binding cluster identified previous MD simulations were considered. In this way, three 
independent replicas for each site were used to calculate averages. The results are shown in Table 1. 
Binding Site Absolute Binding Free Energy (kcal/mol) 
Catalytic Site -5.55±2.28 
Domain II-III Site -8.87±1.59 
Table 1. Absolute binding free energy for Mpro-Ebselen complex for each binding location. The average and uncertainty energy values were obtained 
from 3 independent replicas for each site. Details of the calculation are described in Methods. 
Consistent with the probability density maps shown in Figure 1, the absolute binding free energies corresponding to both 
sites are negative, serving to underscore the thermodynamic stability of the Ebselen-Mpro complex at both sites. Here we 
note the binding affinity of Ebselen at the second binding site, located between the II and III domains, is in fact greater that at 
the catalytic site. A previous report suggested that this small molecule could also inhibit Mpro through non-covalent binding, 
particularly because it has been found to exhibit a stronger inhibition effect than other compounds that were also able to 
modify Cys145 in the catalytic dyad quantitatively (5). The results presented here could explain Ebselen’s high enzymatic 
inhibition, even when this compound could only partially modify Cysteine 145.  
Having identified a distant binding site for Ebselen between domains II and III, we examined the role of this binding site, if 
any, on the catalytic site of the protein. To do so, we determined the local strain induced by the binding throughout the protein. 
To examine potential synergies of drug binding to both sites, we also considered a third scenario in which both sites (catalytic 
and distant) are simultaneously occupied by Ebselen. Note that local strain provides a measure of local deformation that filters 
out non-trivial, functional conformational changes from non-functional ones, and it is therefore ideally suited to highlight how 
a perturbation (i.e. Ebselen binding) at one site induces conformational changes at other, potentially distant, sites. Note that 
different measures of strain have recently been used in studies of allostery in proteins (17, 18, 19). Here, we used a method 
originally introduced by our group in the context of local strain in polymeric glasses. 
Figure 3 shows the shear strain throughout the protein upon binding of Ebselen at different sites, alongside the β-factor 
(estimated from the Root Mean Squared Fluctuation, RMSF), which measures thermal fluctuations for each residue. The 
shear strains are measured relative to the average conformation from all frames of the apo protein trajectory; such strains, 
therefore, correspond to the deformation upon binding relative to the apo protein. The shear strain for the apo structure is 
then showing an average internal strain in the protein.  
From the β-factor analysis, it is evident that when Ebselen is bound to the Domain-II-III interface (Figure 3A: blue lines), the 
dynamics of the 44-52 loop, which flank the catalytic site, is significantly altered. On the other hand, when Ebselen is bound 
at both sites simultaneously there is a clear global reduction of the thermal fluctuations among the receptor except for one 
single region located around residues 137-140, where enhanced flexibility is apparent. Apart from these residues, Ebselen 
bound at both sites shows the lowest β-factor values, however, at this specific point, this system exhibits as high flexibility as 
Mpro-apo protein (Figure 3A: green line). 
 
 
Figure 3. (A) β-factor, estimated from the Root Mean Squared Fluctuation, RMSF, (B) Shear strains. In both upper panels, Mpro apo results are shown 
in green (Mpro-apo); for Ebselen, when bound to the catalytic site (Mpro-EB-Cat), results are in red. For Domain II-III interface (Mpro-Eb-Domain), 
results are shown in blue. For two Ebselen molecules bound at both sites simultaneously (Mpro-Eb-Cat-Domain), results are shown in black. For the 
shear strain calculation, only the Cα atoms are included. (C) Shear strains mapped onto the different protein complexes from (B). The redder the region 
and the larger the radius of the structure, the higher the shear strain. For clarity, only the catalytic site and domain I-II are shown, the drug is shown as 
spheres, and the catalytic dyad as blue sticks.  
 
The strain analysis helps disentangle the effects of functional and non-functional fluctuations and provides a more detailed 
view of the effects of Ebselen binding. As seen in Figure 3A for the β-factor analysis, when Ebselen is bound to the domain 
interface it produces a large strain at the 44-52 loop (Figure 3B: blue line). Likewise, the 185-201 loop that also flanks the 
catalytic site, as well as the region comprising residues 137-140, exhibit a high strain, which is not immediately apparent in 
the β-factor. When both molecules are bound simultaneously to Mpro (Figure 3B, black line), a high strain signal is also 
exhibited around residues 137-140, as expected based on the aforementioned β-factor results. Finally, when Ebselen is 
located in the catalytic site, a much lower strain is showed around all these aforementioned three regions (Figure 3B, red 
line). Figure 3C shows that the strain is primarily localized at the two loops flanking the catalytic site (44-52 and 185-201 
loops), as well as a loop in catalytic site (residues 22-25). A highly strained region also appears around residues 137-140. To 
understand why the 137-140 residues show such a large strain when Ebselen is bound to both sites we turn our attention to 
the molecular images shown in Figure 4. 
 
 
Figure 4. Close-up of the highly strained regions identified from strain analysis. (A) The Mpro structure with Ebselen molecules bound to both catalytic 
site and domain II-III interface simultaneously. In the upper panel, Lys137 and Phe140 are shown as sticks. The lower panel shows the close-up of 
this region and shows the backbone H-bond between Lys137 and Phe140 at the beginning and end of the simulation. (B) The Mpro structure with 
Ebselen bound to domain II-III interface. The close-up shows that a hydrogen bonding interaction is formed with Gln107 side chain, and hydrophobic 
contacts are formed with His246, Val202, Ile249, Phe294, Pro132, and Ile200. This last residue is located at the end of the 185-201 loop which 
connects domain III with domain I-II (Catalytic site). In both (A) and (B) upper figures, Ebselen is shown as spheres and the catalytic dyad as magenta 
sticks.  
 
In the close-up of the residues shown in Figure 4A, a specific backbone hydrogen bond is formed between Lys137 and 
Phe140 due to the binding of Ebselen between domains II and III; this conformational change induced by the presence of 
Ebselen causes the high strain shown in Figure 3B. This conformational change takes place in the middle region between 
the catalytic site (Cys145) and the binding cleft between domains II and III (Pro132), which points to the relevance of these 
residues.  
From these results, it is evident that when Ebselen binds between the II-III domains, it exerts a pronounced allosteric effect 
that affects the loops that regulate access to the catalytic site (44-52 and 185-201 loops). In addition, it affects the residues 
137-140, where a specific backbone hydrogen bond is formed between Lys137 and Phe140. The exact role of this 
conformational change will be the subject of future studies, but the results presented here show that it acts as a relay between 
domain III and the catalytic site.  
Given that conformational changes in the catalytic site are observed when Ebselen binds to Mpro far away from this specific 
region, we turn our attention to the hydration characteristics of the catalytic site in the Mpro-Ebselen complex (when bound to 
domain II-III interface) and in the Mpro-apo structure (PDB code: 6m03) (20). AQUADUCT 1.0.5 (21) was used to analyze the 
water structure and water flux in the Mpro protein, with a time window of 50 ns, and sampling every 1 ps. The results are 
shown in Figure 5. 
 
Figure 5. Upper: Water inlet clusters for (A) apo protein and (B) Ebselen in Domain II-III. The biggest cluster in both cases is divided into three parts 
using K-means (21) and colored for clarity. Lower: Maximum Available Volume (MAV) (as light green surface) and hot-spots (blue-red color and sphere 
radius relative to occupation values) for (A) apo and (B) Ebselen in Domain II-III. The catalytic dyad is represented with sticks (magenta: His41, cyan 
Cys145).  
 
Figure 5 (upper panel) shows that Ebselen binding between Domain II-III leads to fewer water inlets compared with the Mpro 
apo state; this is indicative of a water flux reduction in the catalytic site due upon Ebselen binding, even though it happens far 
from the catalytic site. From the lower panel in Figure 5, it is evident that a volume reduction of the catalytic site occurs when 
Ebselen is located between domain II-III compared with the apo state; the Maximum Available Volume (MAV) for water in the 
catalytic region is around 50% smaller in this case. Note that in the apo protein there is a catalytic water that forms a catalytic 
triad together with Cys145 and His41 (16,23), and this catalytic water (red in Figure 5A lower panel) is preserved and remains 
close to His41 in the simulations. In contrast, it is clear from Figure 5B (lower panel) that the presence of Ebselen induces a 
displacement and reconfiguration of water hotspots, including the catalytic water (red). Importantly, these effects could prevent 
the normal enzymatic function of Mpro, as this catalytic water displacement might damage the catalytic triad that is required 
for protein activity (24). Similarly, the observed pocket volume reduction might affect the accessibility of the polyprotein that 
Mpro cleaves, thereby reducing enzymatic function.  
Conclusion and discussion: 
As mentioned before, Mpro is an attractive drug target against the COVID-19 virus due to is its central role in the viral life 
cycle. A previous structural and evolutionary investigation suggested that the SARS-CoV-2 Mpro is not a suitable target for 
de novo development of inhibitors or the repurposing of drugs against the previous SARS coronavirus (16). That study, 
however, only compared the active sites in Mpro for COVID-19 and the highly similar previous SARS-CoV Mpro in terms of 
flexibility and plasticity, where major differences in both shape and size were observed indicating that repurposing SARS 
drugs for COVID-19 may not be effective. Based on their evolutionary analysis, these authors also pointed out that the virus’s 
mutability will pose further challenges to treatments against the COVID-19 Mpro protein. An alternative to this discouraging 
scenario, however, would be to target the region between the II and III domains, which is implicated in dimer formation. 
Here we find that there are two, highly probable interaction sites between SARS-CoV-2 Mpro and Ebselen. One is located 
within the catalytic cavity and, importantly, a second site is in the region between the II and III domains, which is essential for 
Mpro dimerization (15). Detailed calculations of the free energy reveal a higher binding affinity of Ebselen to the Domain II-III 
than to the catalytic site.  
The strain analysis reveals that Ebselen bound between the II-III domains exert a pronounced allosteric effect that affects the 
loops regulating access to the catalytic site. In addition, it also affects residues 137-140, where a specific backbone hydrogen 
bond is formed between Lys137 and Phe140.  
The catalytic site water analysis indicates that the proposed allosteric inhibition by Ebselen could occur through a volume 
reduction of the catalytic pocket, and a reconfiguration of water hotspots in that region. Given the catalytic role of water in this 
enzyme’s activity, these effects could act to prevent the regular enzymatic function of the SARS-CoV-2 Mpro protein. 
The discovery of a distant binding site is encouraging in that it offers potential for Ebselen as a new drug lead for the design 
and development of new Mpro inhibitors and, eventually, COVID-19 treatment. More generally, this result is helpful in that it 
emphasizes that distant sites could be effective targets for new drugs. Note that current massive virtual screening campaigns 
are focused primarily on targeting the SARS-CoV-2  Mpro catalytic site (25). Of course, additional structural characterization 
experiments are necessary to validate the predictions presented in this work, particularly those pertaining to the distant binding 
site. 
A previous evolutionary study (16) showed that the mutation of a few residues belonging to the catalytic site is energetically 
unfavorable. Therefore, residues such as P39, R40, P52, G143, G146, or L167 could be considered as key anchoring residues 
for Mpro inhibitor design. The insights put forth in this work have the potential to facilitate the rational molecular design of new 
analogs, based on the Ebselen scaffold, that result in anchoring at those positions. This alternative approach, uncovered 
through the extensive molecular simulations presented here, highlights the need to develop reliable, high-throughput methods 
to screen drug-protein interactions at the molecular level and that incorporate the role of explicit water morelcules. We 
conclude by pointing out that our focus in this work has been on non-covalent complexes between Ebselen-Mpro. In a 
subsequent stage, we also plan to investigate covalent complexes involving Cys145.  
Materials and Methods: 
A total of more than 6 μs of classical MD simulations of SARS-CoV-2 Mpro apo state and Mpro-Ebselen complex were run 
using AMBER18 (28) simulation package (3 μs: ebselen as a molecular probe; 2.4 μs: shear strain analysis; 100ns: water 
structure and flux analysis; 990ns: free energy analysis). The receptor initial configuration for the Mpro-Ebselen system was 
taken from recently reported structure for Mpro-N3 inhibitor (5) (PDB ID: 6lu7); where the inhibitor and crystallographic water 
molecules were removed before starting simulations. Force field parameters for Ebselen were determined using the 
Antechamber program and described by the General Amber Force Field (GAFF) (26, 27). The partial atomic charges were 
determined by the restrained electrostatic potential (RESP) fitting technique. Those electrostatic potential calculations were 
performed at the HF/6-31G level with Gaussian 09. For Mpro apo simulations we used the recently reported structure (20), 
(PDB ID: 6m03). Approximately 20,000 TIP3P water model molecules and 4 Na+ ions were added. All simulations were carried 
out using the ff14SB force field (29). The simulation protocol included a first minimization of 7000 steps, involving 3500 
steepest descent steps followed by 3500 steps of conjugate gradient energy minimization, where constraints were applied on 
the protein heavy atoms (force constant 500 kcal x mol-1 x Å2) and a second minimization (7000 steps) with no constraints of 
conjugate gradient energy minimization. Next, during the first equilibration, the temperature was gradually increased from 0 
K to 300 K over 50 ps using a Langevin thermostat with a temperature coupling constant of 1.0 ps in the canonical ensemble. 
Density equilibration and production runs were carried out using a constant pressure ensemble (NPT). All simulations were 
performed using periodic boundary conditions and a 2 fs time step. Long-range electrostatic interactions were calculated 
using the Particle Mesh Ewald method with a non-bonded cut-off of 10 Å and the SHAKE algorithm was used to implement 
rigid constraints.  
Ebselen Global Density map: 
In order to determine the most probable interaction sites between Mpro-Ebselen (global hot-spot), 15 replicas of 200 ns each 
were run (a total of 3 μs), where configurations were saved every 20 ps. The CPPTRAJ (30) software was used to process 
the trajectories, where at the first stage all trajectories were align by means of minimization the distance among protein 
backbone atoms (C, N, CA). Grid command was used to track Ebselen molecule and to produce number density map, where 
the grid resolution was selected to be 0.5 Å.  
Strain analysis:  
Initial Mpro-Ebselen complex configurations were selected from previous global binding affinity study, with Ebselen being 
bound to the catalytic site, to the intersection between Domain II-III, and to both of these sites simultaneously. Three replicas 
of 200 ns for each of these initial setups were run. As a reference simulation, we used the Mpro-apo structure (PDB code: 
6m03), and 3 replicas of 200 ns each were run. In this way, a total of 2400 ns of classical MD were run. 
To apply the strain formalism from continuum theory to discrete, atomistic systems, differential operators replace the 
derivatives (17,18,19,31,32). A radius 𝑅 around each central atom 𝑖 containing 𝑛 other atoms 𝑗 defines the local 
neighborhood around the central atom. The instantaneous position of atom 𝑖 at any timestep in the MD is 𝑥𝑖 , and the position 
of the same atom at any timestep of the reference simulation is 𝑥0,𝑖. To first order, the distances between atom 𝑖 and its 
neighbors 𝑗 are related through the deformation matrix F by 𝑥𝑗 − 𝑥𝑖 = 𝐹(𝑥0,𝑗 − 𝑥0,𝑖), which forms an overdetermined 
system of linear equations, and an optimized 𝐹∗ is sought by minimizing the difference between the actual distances and the 
projected distances to an affine deformation:  𝑚𝑖𝑛 ∑𝑛𝑗=1 [𝑥𝑗 − 𝑥𝑖 − 𝐹(𝑥0,𝑗 − 𝑥0,𝑖)]
2
. The atomic strain tensor is then 
found by 𝜀 =
1
2
(𝐹𝑇𝐹 − 𝐼), and the magnitude is defined as the L2 norm of the shear part of the strain tensor: 𝑇𝑇 (𝑇 −
1
3
𝑇𝑇 𝑇 ∙ 𝐼), 
since proteins are generally incompressible (17,19). For this analysis, a radius of 10 Å around each atom is considered (19), 
and only the Cα atoms are used in the calculations. The reference simulation is the apo protein trajectory and the strain is 
then measured using the Ebselen simulations to elucidate the effect of binding of Ebselen at the different sites.  
In addition, β-factors were estimated over the same trajectories using the atomicfluct command of the CPPTRAJ module of 
Amber18. 
Aqua Duct: 
To analyze the water structure and water flux in the Mpro protein of SARS-CoV-2 we used AQUADUCT 1.0.5 (21). We 
obtained Inlets, Maximum Available Volume (MAV) and Hotspots for water molecules in the Mpro catalytic region. For 
calculations, this region was defined as a 5 Å sphere around the center of geometry of the active site residues (H41, C145, 
H164, D187) (16). The Mpro protein was studied in two different scenarios, with Ebselen in the Domain II-III site and the apo 
protein with no ligand. The time window used in both calculations was 50ns, sampling every 1 ps. Images were created with 
open-source PyMOL (22). 
Free Energy: 
The absolute binding free energy is defined as: ΔGbinding=ΔGL-ΔGRL, where ΔGRL is the free energy change of Ebselen 
annihilation in the Mpro complex, and ΔGL is the free energy change of Ebselen annihilation in water. To calculate these free 
energy changes, we use Thermodynamic Integration (TI) implemented in PMEMD for Amber 18. We use the one step 
anhihilation protocol with soft core potentials (34). In addition, we adopted a simple approach with multiple runs starting from 
the most probably binding cluster estimated from previous MD simulations. In this way, three independent replicas for each 
site were taken into account, as well as three replicas for Ebselen solvated in pure water. Eleven equally spaced windows 
were used (ΔLambda=0.1) with 10ns of simulation time per window. To keep the ligand from wandering in TI calculations, we 
used a soft restraint of 10 kcal/molÅ2 (35). 
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